Tumor specific CTL therapy for advanced cancer and development for cancer vaccine

Hepato-Gastroenterology

Volumn 46, Issue SUPPL. 1, 1999, Pages 1287-1292

  Tsunoda, Takuya ^a   Tanimura, Hiroshi ^a   Yamaue, Hiroki ^a   Tanaka, Hajime ^a   Matsuda, Kenji ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Advanced gastrointestinal cancer; Cancer vaccine; Cytotoxic T lymphocytes; Peptide

Indexed keywords

CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; BILIARY TRACT CANCER; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; FEMALE; FEVER; HUMAN; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; STOMACH CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 0032972610     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Noguchi K, Mizobata S: Clinical efficacy of adoptive immunotherapy by IL-4 activated tumor-infiltrating lymphocytes against advanced cancer patients. Int J Clin Oncol 1997; 2:202-207.
2. Kosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalin SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Eng J Med 1988; 319:1676-1680.
3. Kradin RL, Kurnick JT, Lazarus DS, Pleffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Strauss HW: Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; i:577-580.
4. Ravaud A, Legrand E, Delaunay MM, Bussieres E, Coulon V, Cany L, Huet S, Verdier D, Kind M, Chomy F, Bui BN, Gualde N: A phase I trial of repeated tumour-infiltrating lymphocytes (TIL) infusion in metastatic melanoma. Br J Cancer 1995; 71:331-336.
5. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavane M, Eberlein TJ: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 1995; 13:1939-1949.
6. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, Inoue M: Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy 1990; 4:473-477.
7. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Noguchi K, Hotta T, Mizobata S, Arii K: Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin-4. Br J Cancer 1996; 74:1085-1089.
8. Mizobata S, Tanimura H, Yamaue H, Tani M, Tsunoda T, Iwahashi M, Noguchi K, Nishimoto N, Hotta T, Arii K: Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients. Br J Cancer 1996; 74:1598-1604.
9. Yamaue H, Tanimura H, Mizobata S, Noguchi K, Tani M, Tsunoda T, Iwahashi M, Nakamori M: Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy, Hepato-Gastroenterol 1999; 46:620-625.
10. Yamaue H, Tanimura H, Noguchi K, Mizobata S, Tani M, Iwahashi M, Tsunoda T: Clinical effects of chemoimmunotherapy for patients with peritoneal carcinomatosis. Oncol Rep 1997; 4:583-589.
11. Tani M, Tanimura H, Yamaue H, Mizobata S, Iwahashi M, Tsunoda T, Noguchi K, Tamai M, Hotta T, Terasawa H, Arii K: Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 1995; 60:1-6.
12. Noguchi K, Tanimura H, Yamaue II, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S, Arii K: Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin. J Cancer Res Clin Oncol 1997; 123:345-351.
13. Noguchi K, Tanimura H, Yamaue H, Iwahashi M, Tsunoda T, Tani M, Hotta T, Mizobata S, Arii K, Tamai M: Cisplatin modulates tumor cell susceptibility to tumor-infiltrating lymphocytes in vivo. Oncol Rep 1997; 4:927-930.
14. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M, Iwakura S: Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using MTT assay. Br J Cancer 1992; 66:794-799.
15. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, Tamai M, Hotta T, Arii K: Chemosensitivity testing with highly purified fresh human tumour cells wit the MTT colorimetric assay. Eur J Cancer 1991; 27:1258-1263.
16. Yamaue H, Tanimura H, Nakamori M, Noguchi K, Iwahashi M, Tani M, Hotta T, Murakami K, Ishimoto K: Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 1996; 39:416-422.
17. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff D: Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 1986, 70:1379-1382.
18. Kim NY, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI: A phase III randomized study of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813-3818.
19. Diaz-Ribio E, Jimeno J, Aranda E, Massuti B, Camps C, Cervantes A, Dorta J, Cruz Hernandez JJ, Dominguez S, Anton A, Carrato A, Villar A, Macheng I, Alonso JD, Martos CF, Gonzalez R, Fonseca E, Balana C, Sanchez Hernandez JJ: Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: Negative impact in clinical outcome. Ann Oncol 1992; 3:861-863.
20. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12:412-416.
21. Saikawa Y, Kubota T, Furukawa T, Suto A, Watanabe M, Kumai K, Ishibiki K, Kitajima M: Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 1994; 85:762-765.
22. MacFarlane MP, Yang JC, Guleria AS, White RL, Seipp CA, Einhorn JH, White DE, Rosenberg SA: The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995; 75:1030-1037.
23. Itoh K, Hayakawa K, Salmeron MA, Legha SS, Murray JL, Talpaz M, Balch CM, Parkinson DR, Lee K, Zukiwski AA, Ring SE, LaPushin R, Augustus LB: Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother 1991; 33:238-246.
24. Marchand M, Weynats P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon LJ, Laurent C, Naeyaert MJ, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie PG, Boon T: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-885.
25. Nestle OF, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Medi 1998; 4:328-332.
26. Rosenberg SA, Yang CJ, Schwartzentruber JD, Hwu P, Marincola MF, Topalian LS, Restifo PN, Dudley EM, Schwarz LS, Spiess JP, Wunderlich RJ, Parkhurst RM, Kawakami Y, Seipp AC, Einhorn HJ, White KD: Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medi 1998; 4:319-327.